chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient was given the diluent only for the Menveo (meniningococcal vaccine).  No adverse affects were noted. The patient was reimmunized on 10/27/2015 with the full dose of vaccine. The error was noted in the chart.
stroke; unresponsive; unable to move one side of her body; fell down the stairs; fever; felt groggy; This is a spontaneous report from a contactable consumer and a non-contactable consumer (patient's sister). A 37-year-old female patient received 1st dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 14Jan2021 at single dose for an covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient was an oncology nurse practitioner working received the Pfizer BioNtech vaccine on Thursday 14Jan2021. On Friday 15Jan2021, the patient visited her family members and told them she had a fever and felt groggy. She went to sleep around 8pm-9pm that evening (15Jan2021). Around 2am-3am in the morning Saturday 16Jan2021, the patient fell down the stairs and her family member found her - unresponsive and unable to move one side of her body. Her family member moved her to the couch. Around 7am-7:30am, the patient was still unresponsive and unable to move one side of her body. Her family dialed an ambulance took her to an hospital. At present - her family reported that the healthcare professional they spoke to said the patient had a stroke. She had received multiple scans (MRI, brain scan) in the hospital and was awaiting a Neuro consult. It was unknown if treatment received. The outcome of events was unknown.  Information about lot/batch number has been requested.
>35 days from the first dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (>35 days from the first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (>35 days from the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (>35 days from the first dose) had resolved.            No concomitant medications reported. The patient reported that a few things had happened that prevented her from going to get the second vaccine. No treatment medications reported.
Information was received on 23-OCT-2017 from a lawyer regarding a case in litigation concerning a male patient of unknown age. The patient was inoculated with a dose of ZOSTAVAX vaccine on or about 20-JUN-2016 at a pharmacy, as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. About a week after being vaccinated, the patient began to experience painful symptoms. On or about 28-JUN-2016, the patient was treated by a nurse practitioner for the onset of a severe vesicular rash accompanied by weakened immune systems, which was diagnosed as herpes zoster or shingles. On or about 08-OCT-2016, the patient sought subsequent treatment from a physician for ongoing and worsening symptoms of shingles and nerve pain, which was diagnosed as post-herpetic neuralgia, a chronic condition of nerve damage and residual pain secondary to zoster infections. The patient has been prescribed gabapentin (manufacturer unknown) for management of his painful condition. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Pt broke out with rash at 6:45. Received flu shot at clinic at 2:00 pm. I've been getting flu shots for years. Describes broke out in hives and itching relieved with Benadryl. Took at 10 AM and AM Advised to call Dr.
DAY AFTER 2ND SHOT RED ARM, SWOLLEN LYMPH IN NECK AND ARM BP AND SOB STARTED WITHIN 1 WEEK.  CONTINUED STILL.  BP IS NOT CONTROLLED  AND CONTINUE WITH SOB
Information has been received from a Physician's Assistant concerning a 16 year old female patient who on an unspecified dates was vaccinated with all three doses of GARDASIL. Three months later the patient experienced seizures. At the time of the report the patient's outcome was unknown. The patient sought unspecified medical attention. Upon internal review seizures was considered to be an other important medical event. Additional information has been requested.
This case was extracted from the VAERS database via OSCAN on 24 February 2009 (reference numbers 336106 and 335552). A 26-year-old female patient received intramuscular injections of Fluzone SV 2008-2009 (lot number U2848AA) and Adacel (lot number C3027AA) on 17 December 2008. One hour post-vaccination, she developed red eyes, a cough, and was "stopped up". She was instructed to report to the emergency department for evaluation; no additional information was reported.
recently came in contact with a friend who had the Moderna vaccine she was also getting frozen shoulder; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PERIARTHRITIS (recently came in contact with a friend who had the Moderna vaccine she was also getting frozen shoulder) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIARTHRITIS (recently came in contact with a friend who had the Moderna vaccine she was also getting frozen shoulder). At the time of the report, PERIARTHRITIS (recently came in contact with a friend who had the Moderna vaccine she was also getting frozen shoulder) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       Concomitant medication not reported. Treatment medication not reported.  Company comment.  This spontaneous case concerns a female patient (unknown age), with no medical history reported, who received a dose of mRNA  1273 original vaccine and experienced the unexpected, non  serious AESI of periarthritis. Latency cannot be properly assessed since exact onset date and vaccination date were not provided. No information about patient´s immunisation schedule was disclosed. The report stated that the patient experienced frozen shoulder and that "she has been dealing with an arm that has not worked for over a year". The outcome of the event was unknown. No further clinical details were provided for medical reviewing. The benefit-risk relationship of mRNA  1273 original vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-714274, US-MODERNATX, INC.-MOD-2023-714276 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-714276:(Case 30 Peoples) US-MODERNATX, INC.-MOD-2023-714274:(Tracking only case for Repoter))
Right upper area became swollen and red at injection site. Rash developed on right arm, chest, left ram, torso, and private areas on 10-22-15.
Woke up the next day with shingles have had leukocytosis since then.
Potentially injected vaccine into the subcutaneous fat beneath the deltoid; A spontaneous report was received from a pharmacist concerning a male patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced potentially injected vaccine into the subcutaneous fat beneath the deltoid.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On an unknown date, the patient received the first dose of mRNA-1273 for prophylaxis of COVID-19 infection, after that the patient experienced fever and chills, which was resolved within 24 hours.  On an unknown date, the patient received their second dose of mRNA-1273 subcutaneously for prophylaxis of COVID-19 infection.  On an unknown date, the patient's second dose was administered by a nurse who squeezed the recipient's arm and potentially injected vaccine into the subcutaneous fat beneath the deltoid. The patient did not experience symptoms after their second dose. No treatment information was provided.   There was no change planned to the dosing schedule of mRNA-1273 in response to the events fever and chills. The patient received both scheduled doses of mRNA-1273 prior to the event potentially injected vaccine into the subcutaneous fat beneath the deltoid, therefore action taken with the drug in response to the event is not applicable.  The events, potentially injected vaccine into the subcutaneous fat beneath the deltoid was considered resolved. The outcome of the events fever and chills were unknown.; Reporter's Comments: This report refers to a case of product administration error for mRNA-1273, where the vaccine was administered into the subcutaneous fat. There were no reported AEs associated with this case of incorrect route of product administration.
Woke up around 2am with intense body aches - unable to get comfortable or sleep.  For the next 24 hours had body aches, muscle fatigue and severe headache.  Once symptoms improved they improved substantially.  The next day my head hurt only when I would bend down (e.g. to pick something up off the floor), and my fingers hurt when I was typing.  The day after that, good as new.
Child experienced high fever,  99.5 fever along with other side effects including body pains, chills, headaches for several days. Additionally child experienced acute onset new symptoms including extremely elevated anxiety, nonstop worries and fears, irrational thoughts, OCD thoughts and behaviors,  separation anxiety, lying on couch under a blanket for hours and scared of the entire world, requiring nonstop reassurance, unable to function with virtual school or focus and had to be removed from school for the remainder of the school year, restricted eating  and fears to eat , psychosis, inability to complete daily functions, severe sleep disruption and lack of sleep, challenges showering, dressing and bathing self,  repetitive speech, blank stares, dilated pupils, electric like jolts of pain sensation in his brain and head, crying and emotional, anger outbursts and aggression, tingling in all of his limbs, tics and other neurological symptoms, need for significant medical treatment from three specialists/ doctors including neurology/ immunology/ pediatrician and ER visit and many labs for the last five months plus. Needed to have significant special education support and IEP in place upon return from school and 1:1 case manager and much assistance from staff to function daily.
This case was reported by a consumer via call center representative and described the occurrence of injection site bruising in a 63-year-old male patient who received SHINGRIX for prophylaxis. Concurrent medical conditions included Crohn's disease. On 2nd April 2019, the patient received the 2nd dose of SHINGRIX (intramuscular). On 3rd April 2019, 1 days after receiving SHINGRIX, the patient experienced tiredness and weakness. On 5th April 2019, the patient experienced painful rash. In April 2019, the patient experienced injection site bruising. On an unknown date, the outcome of the injection site bruising and painful rash were not recovered/not resolved and the outcome of the tiredness and weakness were recovered/resolved. It was unknown if the reporter considered the injection site bruising, tiredness, weakness and painful rash to be related to SHINGRIX. Additional details were reported as follows: This case was reported by the patient for himself. The patient received a dose of SHINGRIX vaccine on the left shoulder. Next day of vaccination he started experiencing tiredness and weakness, which had resolved. At the time of reporting 3 days after receiving SHINGRIX, the patient experienced a round rash associated with pain about 2 to 3 inches below the injection site which was 3 inches in diameter. The patient also mentioned less than a week after receiving SHINGRIX, the site below the injection site was black and blue. The reporter consented to follow up. This case has been linked with case US2019061869, reported by same reporter.
Woke up with swollen, tender lump in left side groin on Tuesday morning (following shot on previous Friday). Size of a small plum the first day, decreasing in size & tenderness on subsequent days.  Almost resolved 14 days later.   Mild injection site pain on days 1-4 after shot, resolved in a few days. Small bruising at injection site on day 8 (after having no visible mark for the first week?!) Resolved by day 14.
experiencing diarrhea; possible rash sensation on her arms; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (experiencing diarrhea) and RASH (possible rash sensation on her arms) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (experiencing diarrhea) and RASH (possible rash sensation on her arms). On 19-Jul-2021, DIARRHOEA (experiencing diarrhea) and RASH (possible rash sensation on her arms) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 31-Jul-2021: significant follow up received: Reporter's Email Id, Phone Number is reported. Patient's height and weight is reported. Event outcome is reported.
Upper respiratory reaction with drainage, sore throat, and eye irritation.  By 8:00pm spiked temp of 101 and chills.  The next day minor sore throat but everything else resolved.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 71-year-old female patient who received SHINGRIX (batch number 9349T, expiry date 7th March 2021) for prophylaxis. On 30th August 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 31st August 2018, 1 days after receiving SHINGRIX, the patient experienced injection site erythema, rash and welts. The patient was treated with BENADRYL (NOS). On an unknown date, the outcome of the injection site erythema, rash and welts were recovered/resolved. It was unknown if the reporter considered the injection site erythema, rash and welts to be related to SHINGRIX. Additional details were provided as follows: At 13:10 hours, the patient received the SHINGRIX vaccine in the left deltoid.The next day after the vaccination, she experienced redness at the injection site and a rash on her trunk and back.The rash was described as almost resembling whelps. She took BENADRYL and the symptoms were fully resolved quickly. The reporter was unable to provide additional information. The reporter provided the lot number 93492. Explained that this number did not correlate with the SHINGRIX product. She did not know the actual lot number. The reported batch number of SHINGRIX was updated from 93492 to 9349T, as per sales data sheet.
Get the HepB vaccines / I did / A "titer" test / showed I didn't have any antibodies against HepB; This case was reported by a other health professional via interactive digital media and described the occurrence of therapy non-responder in a adult patient who received Hepatitis B vaccine for prophylaxis.   On an unknown date, the patient received Hepatitis B vaccine. On an unknown date, several years after receiving Hepatitis B vaccine, the patient experienced therapy non-responder. On an unknown date, the outcome of the therapy non-responder was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient worked in healthcare for 30 yrs and was recommended the HepB vaccines and patient received. Several years later had blood drawn for a titer test and it showed and did not had any antibodies against HepB. The reporter siblings and patient had our childhood shots. All but one of us was fine. The patient eldest sister not at all and developed encephalitis which was one of the rarest side effects and was fine until 8 yrs old when started having seizures and falling down a lot.  By the time the patient sister was 10 and could no longer walk talk or even sit up or feed and eventually developed cerebral palsy and lost most of her sight and hearing. The patient sister lived until was 30 but had to live in a nursing facility due to the high level of care required. It was def a catastrophic disease and it changed the whole course of family's life.  The reporter asked could vaccine cause terrible side effects that can affect the rest of life. The vaccines are not to be taken lightly and take several years to properly study and test. Even if the vaccine was taken it did not guarantee that would developed antibodies anyway. This case linked with US2020AMR254828, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR254828:Same reporter
patient age 8 years old; The shot was given at 2:30pm.  By 4pm we noticed significant eye swelling and irritation.  Gave him a full adult dose of Benadryl (25mil) and contacted our pediatrician.  By 5 eyes were nearly swelled; The shot was given at 2:30pm.  By 4pm we noticed significant eye swelling and irritation.  Gave him a full adult dose of Benadryl (25mil) and contacted our pediatrician.  By 5 eyes were nearly swelled; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 8 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 18Nov2021 14:30 (Lot number: FK5127) at the age of 8 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Known allergies: Egg" (unspecified if ongoing), notes: Egg; "Known allergies: peanuts" (unspecified if ongoing), notes: peanuts; "Known allergies: tree nuts" (unspecified if ongoing), notes: tree nuts. There were no concomitant medications. The following information was reported: EYE SWELLING (medically significant), EYE IRRITATION (medically significant) all with onset 18Nov2021 16:00, outcome "recovered" (Nov2021) and all described as "The shot was given at 2:30pm.  By 4pm we noticed significant eye swelling and irritation.  Gave him a full adult dose of Benadryl (25mil) and contacted our pediatrician.  By 5 eyes were nearly swelled". The event "the shot was given at 2:30pm.  by 4pm we noticed significant eye swelling and irritation.  gave him a full adult dose of benadryl (25mil) and contacted our pediatrician.  by 5 eyes were nearly swelled" and "the shot was given at 2:30pm.  by 4pm we noticed significant eye swelling and irritation.  gave him a full adult dose of benadryl (25mil) and contacted our pediatrician.  by 5 eyes were nearly swelled" was evaluated at the physician office visit. Therapeutic measures were taken as a result of eye swelling, eye irritation.  Additional information: After first dose of Benadryl it took approximately 18 hours (and a second and third dose of Benadryl) for his eye swelling to completely go away. The patient did not have any other vaccine in 4 weeks. The patient did not have any other medication in two weeks. The patient did not have covid-19 prior vaccination and the patient did not tested for covid-19 post vaccination.
Fever 7 days post vaccinations (9-20-13) started at 1:30 am, clingy, fussy, restless. No runny nose, nasal congestion, no cough.
Beginning 7 days post-injection there was itching, a hard bump and redness in a circle form, measuring approximately 3",  gradually lessening until gone 10 days after noticing this.
HAD PAIN AT IMMUNIZATION SITE AFTER THE INJECTION BUT NOTICED REDNESS ON THE INSIDE OF THE ARM 1 WK LATER W/PAIN.
It was reported that a 51 year old male pt received Fluzone WV '98-'99 USP on 11/3/98. Reportedly, sometime, post vax, the pt experienced a hot area 1cm below injection site. From additional information received on 11/20/1998, it was reported that the pt recovered from this experience.
having hives in some part of her body like in the  wrist and knees; This is a spontaneous case received from a contactable consumer (patient). A female patient of an unspecified age received first dose of bnt162b2 (Pfizer COVID 19 Vaccine, Formulation: solution for injection, Lot number: not reported) via an unspecified route of administration on 08Mar2021 as 1ST DOSE, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On Mar2021, the patient having hives in some part of her body like in the wrist and knees. The patient reported that the hives was occasionally. She mentioned that regarding the condition is it possible to take the second dose and having the same reaction. The outcome of the event was unknown.    Follow-up attempts completed. No further information expected.
I developed a sore throat after I got home from my shift (Finished at 8pm). Approx 815pm I noticed I had a sore throat. This continued into the next day with mild total body aches and fatigue. By Saturday 1/16/21 I felt 100% fine.
It was reported that a 55 year old female pt received a TD Adult vaccination on 03/14/2002. On 03/21/2002 the pt came to ER with large local reaction of redness, swelling and soreness. Physician diagnosed cellulitis and prescribed antibiotics. Reporter stated that pt did not respond to the antibiotics so she was admitted to the hospital on 03/21/2002 and discharged 03/22/2002.
tingling and numbness kind of like numbing sensation all over body; numbness kind of like numbing sensation all over body; This is a spontaneous report from a contactable consumer (patient).   A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection; Batch/Lot number: Unknown, Expiration date: Unknown) via an unspecified route of administration on 24Jan2021 as unknown, single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported.  On an unspecified date of Jan2021 after vaccination, the patient experienced tingling and numbness kind of like numbing sensation all over body. It was reported that patient was able to walk around and could work. Patient was feeling fine thought having events. Patient had no fever, no shortness of breath and O2 stats were normal. Outcome of events was unknown.   Follow-up attempts are completed. No further information is expected.
Patient had several immunizations in both his right and left thigh on 8/10/16. On the morning of 8/18/16, the patient's mother noticed redness on the right leg. It appeared to be itchy. On 8/19/16, he was evaluated in the office by NP and patient had right upper thigh with erythematous raised lesion. + blanchable. No fluctuance and nontender.
Large red swollen area about size of orange on (L) upper arm. Warm compresses and Benadryl
APAP was given as advised; pt had 2 hrs uncontrollable crying; no fever; parent took it temp twice; parent notified MD; MD felt pt should have ped DT in future;
All Covid-19 symptoms including loss of taste, sore throat, aches, chills, low grade fever, cough
w/in 1st 24 hrs p/vax administered became very paranoid w/explosive behavior lasting approx 24 hrs;